Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Rovelizumab> ?p ?o }
Showing triples 1 to 69 of
69
with 100 triples per page.
- Rovelizumab abstract "Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. Rovelizumab was developed by Icos to treat patients suffering from haemorrhagic shock. The drug is a monoclonal antibody that suppresses white blood cells which become overly active during shock. During testing the number of patients given the drug was low because rovelizumab had to be delivered within four hours of the injury and consent was required. Often the patient was unconscious and relatives had to be reached to give consent. In June 1998, Icos and many medical centers asked the United States Food and Drug Administration (FDA) to waive consent requirements in situations where the patient was at high risk of dying and relatives could not be reached. While some medical ethicists opposed waiving consent, the FDA approved the proposal in August 1998 for five medical centers. Development of rovelizumab was halted in April 2000 when interim data from phase III clinical trials did not meet Icos's goals. The company's goals for rovelizumab included reducing the chance of multiple organ failure and reducing the death-rate from shock at 28 days. Rovelizumab was also being tested for treating heart attack, multiple sclerosis, and stroke, and was being explored as a treatment for cerebral vasospasm, head trauma, kidney transplantation, and restenosis.Multiple companies have tried to develop anti-CD18 drugs, but none of them have been successful. Among them are Genentech's erlizumab, and two drugs developed by Protein Design Labs (PDL) and Centocor. Although trials in humans have not gone well, the research of anti-CD18 drugs in animals has been encouraging. It is thought that the experimental medicines are affecting the lymphocyte adhesion pathway in humans in unintended ways.".
- Rovelizumab atcPrefix "none".
- Rovelizumab casNumber "197099-66-4".
- Rovelizumab wikiPageID "9134281".
- Rovelizumab wikiPageLength "5490".
- Rovelizumab wikiPageOutDegree "20".
- Rovelizumab wikiPageRevisionID "592957887".
- Rovelizumab wikiPageWikiLink CD11.
- Rovelizumab wikiPageWikiLink CD18.
- Rovelizumab wikiPageWikiLink Category:Monoclonal_antibodies.
- Rovelizumab wikiPageWikiLink Centocor.
- Rovelizumab wikiPageWikiLink Erlizumab.
- Rovelizumab wikiPageWikiLink Food_and_Drug_Administration.
- Rovelizumab wikiPageWikiLink Genentech.
- Rovelizumab wikiPageWikiLink Head_injury.
- Rovelizumab wikiPageWikiLink Head_trauma.
- Rovelizumab wikiPageWikiLink Heart_attack.
- Rovelizumab wikiPageWikiLink Humanized_antibody.
- Rovelizumab wikiPageWikiLink Humanized_monoclonal_antibody.
- Rovelizumab wikiPageWikiLink Icos.
- Rovelizumab wikiPageWikiLink Immunosuppressive_drug.
- Rovelizumab wikiPageWikiLink Informed_consent.
- Rovelizumab wikiPageWikiLink Janssen_Biotech.
- Rovelizumab wikiPageWikiLink Kidney_transplantation.
- Rovelizumab wikiPageWikiLink Multiple_sclerosis.
- Rovelizumab wikiPageWikiLink Myocardial_infarction.
- Rovelizumab wikiPageWikiLink Restenosis.
- Rovelizumab wikiPageWikiLink Shock_(circulatory).
- Rovelizumab wikiPageWikiLink Stroke.
- Rovelizumab wikiPageWikiLink White_blood_cell.
- Rovelizumab wikiPageWikiLinkText "LeukArrest".
- Rovelizumab wikiPageWikiLinkText "Rovelizumab".
- Rovelizumab wikiPageWikiLinkText "rovelizumab".
- Rovelizumab atcPrefix "none".
- Rovelizumab casNumber "197099".
- Rovelizumab chemspiderid "NA".
- Rovelizumab hasPhotoCollection Rovelizumab.
- Rovelizumab mabType "mab".
- Rovelizumab source "zu/o".
- Rovelizumab target CD11.
- Rovelizumab target CD18.
- Rovelizumab tradename "LeukArrest".
- Rovelizumab type "mab".
- Rovelizumab verifiedfields "changed".
- Rovelizumab verifiedrevid "464384004".
- Rovelizumab wikiPageUsesTemplate Template:Drugbox.
- Rovelizumab wikiPageUsesTemplate Template:Immunosuppressants.
- Rovelizumab wikiPageUsesTemplate Template:Monoclonals_for_immune_system.
- Rovelizumab wikiPageUsesTemplate Template:Reflist.
- Rovelizumab subject Category:Monoclonal_antibodies.
- Rovelizumab hypernym Antibody.
- Rovelizumab type Article.
- Rovelizumab type ChemicalSubstance.
- Rovelizumab type Drug.
- Rovelizumab type Antibody.
- Rovelizumab type Article.
- Rovelizumab type Chemical.
- Rovelizumab type Drug.
- Rovelizumab type ChemicalObject.
- Rovelizumab type Thing.
- Rovelizumab type Q8386.
- Rovelizumab comment "Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. Rovelizumab was developed by Icos to treat patients suffering from haemorrhagic shock. The drug is a monoclonal antibody that suppresses white blood cells which become overly active during shock. During testing the number of patients given the drug was low because rovelizumab had to be delivered within four hours of the injury and consent was required.".
- Rovelizumab label "Rovelizumab".
- Rovelizumab sameAs Rovelizumab.
- Rovelizumab sameAs m.027yyyk.
- Rovelizumab sameAs Q3941929.
- Rovelizumab sameAs Q3941929.
- Rovelizumab wasDerivedFrom Rovelizumab?oldid=592957887.
- Rovelizumab isPrimaryTopicOf Rovelizumab.